(via NewsDirect)
Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, a nasal gel that decolonizes patients before surgery to prevent post-surgical infections.
He adds that the asset is now "very well positioned" for a partnering programme.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source